Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Skyrizi
Biotech
Oruka’s psoriasis data hailed as ‘outright win over Skyrizi’
Jefferies analysts predicted the asset could beat out AbbVie’s Skyrizi and generate sales of up to $10 billion.
Nick Paul Taylor
Apr 27, 2026 9:51am
AbbVie ends development of IL-1 asset in ulcerative colitis
Jul 31, 2025 12:32pm
Fierce Pharma
AbbVie will continue to pursue external innovation for long-term
Jul 31, 2025 11:44am
Innovent looks to Chinese regulators after ph. 3 psoriasis win
May 28, 2024 7:55am
AbbVie coughs up nearly $50M for Cugene's autoimmune med
May 16, 2022 10:05am
